TWi Biotechnology, Inc(TW:6610)
NT$17.50-0.05 (-0.28%)
TW:6610
TWi Biotechnology, Inc financials statements
NT$17.50
At close:-0.05 (-0.28%)
TWi Biotechnology, Inc (6610) Ratios
TWi Biotechnology, Inc Ratios
TW:6610's free cash flow for Q2 2026 was NT$-151.15M. For the 2026 fiscal year, TW:6610's free cash flow was decreased by NT$-126.00K and operating cash flow was NT$-151.02M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.98 | 2.93 | 6.85 | 6.32 | 8.48 |
| Quick Ratio | 2.98 | 2.93 | 6.85 | 6.32 | 8.48 |
| Cash Ratio | 2.93 | 2.09 | 3.20 | 6.26 | 7.01 |
| Solvency Ratio | -1.79 | -2.33 | -2.88 | -2.32 | -0.13 |
| Operating Cash Flow Ratio | -3.18 | -2.56 | -2.83 | -2.35 | -1.28 |
| Short-Term Operating Cash Flow Coverage | -105.63 | -15.54 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 175.36M | NT$ 111.57M | NT$ 269.11M | NT$ 133.58M | NT$ 196.44M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.06 | 0.02 | 0.01 | 0.02 |
| Debt-to-Equity Ratio | 0.00 | 0.09 | 0.02 | 0.01 | 0.02 |
| Debt-to-Capital Ratio | 0.00 | 0.08 | 0.02 | 0.01 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.15 | 1.38 | 1.16 | 1.14 | 1.12 |
| Debt Service Coverage Ratio | -111.55 | -15.25 | -1848.93 | -1370.35 | -47.81 |
| Interest Coverage Ratio | -2137.86 | -1136.87 | -1948.92 | -1878.67 | -177.92 |
| Debt to Market Cap | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.17 | 0.10 | 0.04 | 0.07 |
| Net Debt to EBITDA | 0.81 | 0.72 | 0.89 | 2.40 | 44.70 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 98.62% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | -22.91% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | -6.19% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -23.04% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -23.04% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -23.04% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -23.04% |
| Net Income Per EBT | 56.61% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 100.14% | 92.33% | 100.66% | 84.48% | 99.97% |
| Return on Assets (ROA) | -27.97% | -68.01% | -43.01% | -32.51% | -4.92% |
| Return on Equity (ROE) | -32.10% | -93.72% | -50.05% | -36.99% | -5.49% |
| Return on Capital Employed (ROCE) | -56.36% | -98.31% | -48.53% | -43.21% | -5.39% |
| Return on Invested Capital (ROIC) | -56.12% | -91.91% | -48.20% | -42.70% | -5.34% |
| Return on Tangible Assets | -68.15% | -78.83% | -47.73% | -40.29% | -5.90% |
| Earnings Yield | -6.21% | -12.71% | -15.65% | -7.92% | -1.43% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 16.08 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 6.96 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.40 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 22.69 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 22.69 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 22.69 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.48 | -1.67 | -1.73 | -0.89 | -0.49 |
| Free Cash Flow Per Share | -1.48 | -1.68 | -1.73 | -0.89 | -0.92 |
| Dividend Paid and CapEx Coverage Ratio | -705.14 | -504.59 | -1.00 | 0.00 | -1.14 |
| Capital Expenditure Coverage Ratio | -705.14 | -504.59 | -1.00 | 0.00 | -1.14 |
| Operating Cash Flow Coverage Ratio | -97.42 | -9.96 | -16.84 | -23.83 | -6.86 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.52 |
| Free Cash Flow Yield | -8.82% | -12.01% | -12.31% | -6.26% | -6.03% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -16.15 | -7.88 | -6.39 | -12.62 | -69.41 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 16.15 |
| Price-to-Book (P/B) Ratio | 5.17 | 7.37 | 3.20 | 4.67 | 3.85 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.34 | -8.33 | -8.13 | -15.96 | -16.58 |
| Price-to-Operating Cash Flow Ratio | -11.36 | -8.34 | -8.13 | -15.96 | -31.12 |
| Price-to-Earnings Growth (PEG) Ratio | 0.39 | 0.40 | -0.07 | -0.03 | 0.82 |
| Enterprise Value Multiple | -9.32 | -7.65 | -5.89 | -12.22 | -216.07 |
| Enterprise Value | 3.00B | 1.19B | 946.76M | 803.74M | 888.47M |
| EV to EBITDA | -9.32 | -7.65 | -5.89 | -12.22 | -216.07 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 13.38 |
| EV to Free Cash Flow | -10.43 | -7.61 | -7.05 | -13.34 | -13.74 |
| EV to Operating Cash Flow | -10.45 | -7.63 | -7.05 | -13.34 | -25.78 |
| Tangible Book Value Per Share | 1.05 | 1.53 | 3.89 | 2.38 | 3.23 |
| Shareholders’ Equity Per Share | 3.25 | 1.89 | 4.39 | 3.05 | 3.97 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.95 |
| Net Income Per Share | -1.04 | -1.77 | -2.20 | -1.13 | -0.22 |
| Tax Burden | 0.57 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.42 | 0.94 | 0.79 | 0.79 | 2.25 |
Currency in TWD
